Skip to main content
Hit enter to search or ESC to close
Cortical and lesion remyelination in relapsing-remitting multiple sclerosis patients from the Opicinumab (Anti-LINGO-1) phase II clinical trial (Synergy). A validation study of the T1-weighted and T2-weighted ratio approach (RAPOR)
© 2023 VHIR Annual Report 2021.
Six Top Stories
Facts & Figures
Partners and Acknowledgements
VHIR Annual Report 2021